19867-34-6

Basic information

• Product Name: 6-benzyl-1-oxa-6-azaspiro[2,5]octane
• Synonyms: 6-benzyl-1-oxa-6-azaspiro[2,5]octane;6-(Phenylmethyl)-1-oxa-6-azaspiro[2.5]octane;Einecs 243-383-1
• CAS NO: 19867-34-6
• Molecular Formula: C₁₃H₁₇NO
• Molecular Weight: 203.28018
• EINECS: 243-383-1
• Mol File: 19867-34-6.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 302.1°Cat760mmHg
• Flash Point: 89.1°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 0.00101mmHg at 25°C
• Refractive Index: 1.586
• CAS DataBase Reference: 6-benzyl-1-oxa-6-azaspiro[2,5]octane(CAS DataBase Reference)
• NIST Chemistry Reference: 6-benzyl-1-oxa-6-azaspiro[2,5]octane(19867-34-6)
• EPA Substance Registry System: 6-benzyl-1-oxa-6-azaspiro[2,5]octane(19867-34-6)

Safety Data

• Hazardous Substances Data: 19867-34-6(Hazardous Substances Data)

Usage

General Description

6-benzyl-1-oxa-6-azaspiro[2,5]octane is a chemical compound that belongs to the spiro compounds class. It is a heterocyclic compound containing a benzyl group and a spiro-fused bicyclic ring system. 6-benzyl-1-oxa-6-azaspiro[2,5]octane has potential applications in medicinal chemistry and drug discovery due to its unique structure and potentially interesting biological activities. Its spiro configuration makes it a valuable building block for the development of new pharmaceuticals with diverse pharmacological properties. Additionally, spiro compounds are known for their stability and resistance to degradation, making 6-benzyl-1-oxa-6-azaspiro[2,5]octane a promising candidate for further research and development in the field of drug design and synthesis.

InChI:InChI=1/C13H17NO/c1-2-4-12(5-3-1)10-14-8-6-13(7-9-14)11-15-13/h1-5H,6-11H2

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 74-95-3 1,1-dibromomethane 
• 793-19-1 bis(2-methoxycarbonylethyl)benzylamine 
• 100-46-9 benzylamine 
• 2181-42-2 trimethylsulphonium iodide 
• 1774-47-6 trimethylsulfoxonium iodide 
• 41979-39-9 4-piperidone hydrochloride 
• 59502-05-5 benzyl chloride-d7 

Downstream Products

• 22065-85-6 N-benzyl-4-formylpiperidine 
• 23804-68-4 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine 
• 574747-40-3 spiro[(2,3-dihydro-1,4-benzodioxine)-2,4'-(N-benzylperidine)] 
• 574747-39-0 N-benzyl-4-(2-fluorophenoxymethyl)-4-hydroxypiperidine 
• 91546-55-3 3-methylene-cis-8-benzyl-1-oxa-8-azaspiro<4.5>decan-2-one 
• 92197-36-9 4-hydroxy-4-(hydroxymethyl)-1-(phenylmethyl)piperidine 
• 477721-53-2 methyl 4-[(1-benzyl-4-hydroxypiperidin-4-ylmethyl}-methylamino)benzoate 
• 1357011-81-4 1-benzyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-4-ol 
• 1357011-87-0 4-fluoro-N-[3-[4-hydroxy-4-(2-methyl-1H-benzo[d]imidazol-1-ylmethyl)-piperidin-1-yl]-1-phenylpropyl]benzamide 
• 1357011-88-1 4-fluoro-N-[3-[4-hydroxy-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-1-phenylpropyl]benzamide 
• 1357011-89-2 N-[3-[4-(9H-carbazol-9-ylmethyl)-4-hydroxypiperidin-1-yl]-1-phenylpropyl]-4-fluorobenzamide 
• 1357011-90-5 N-[3-[4-(1H-benzo[d][1,2,3]triazol-1-ylmethyl)-4-hydroxypiperidin-1-yl]-1-phenylpropyl]-4-fluorobenzamide 
• 1357011-91-6 N-[3-[4-(1H-benzo[d]imidazol-1-ylmethyl)-4-hydroxypiperidin-1-yl]-1-phenylpropyl]-4-fluorobenzamide 
• 1357011-92-7 4-fluoro-N-[3-[4-hydroxy-4-(1H-indol-1-ylmethyl)piperidin-1-yl]-1-phenylpropyl]benzamide 

Relevant articles and documents

Novel and efficient method to synthesize N-benzyl-4-formyl-piperidine

A novel and efficient method was developed to synthesize N-benzyl-4-formyl-piperidine, a key intermediate of Donepezil (Aricept). N-Benzyl-4-piperidone was reacted with dimethyloxosulfonium methylide to get epoxide, followed by rearrangement in the presence of magnesium bromide etherate to give target compound in high yield.

4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain

The synthesis and pharmacological activity of a new series of 1-oxa-4,9-diazaspiro[5.5]undecane derivatives as potent dual ligands for the sigma-1 receptor (σ1R) and the μ-opioid receptor (MOR) are reported. The different positions of the central scaffold, designed using a merging strategy of both target pharmacophores, were explored using a versatile synthetic approach. Phenethyl derivatives in position 9, substituted pyridyl moieties in position 4 and small alkyl groups in position 2 provided the best profiles. One of the best compounds, 15au, showed a balanced dual profile (i.e., MOR agonism and sigma antagonism) and a potent analgesic activity, comparable to the MOR agonist oxycodone in the paw pressure test in mice. Contrary to oxycodone, as expected from the addition of σ1R antagonism, 15au showed local, peripheral activity in this test, which was reversed by the σ1R agonist PRE-084. At equianalgesic doses, 15au showed less constipation than oxycodone, providing evidence that dual MOR agonism and σ1R antagonism may be a useful strategy for obtaining potent and safer analgesics.

Continuous Flow Synthesis of Terminal Epoxides from Ketones Using in Situ Generated Bromomethyl Lithium

A scalable procedure for the direct preparation of epoxides from ketones has been developed. The method is based on the carefully controlled generation of (bromomethyl)lithium (LiCH2Br) from inexpensive CH2Br2 and MeLi in a continuous flow reactor. The reaction has shown excellent selectivity for a variety of substrates, including α-chloroketones, which typically fail under classic Corey-Chaykovsky conditions. This advantage has been used to develop a novel route toward the drug fluconazole.